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Objective: The purpose of this study was to test the hypothesis that the long-term outcome of infrainguinal bypass grafting
in patients with congenital or acquired hypercoagulability is inferior to the results in patients without documented
clotting disorders.
Methods: The study was a retrospective analysis of consecutive patients from January 1994 to January 2001.
Results: Five hundred eighty-two infrainguinal bypass grafts were created in 456 patients. Indication for surgery was
limb-threatening ischemia in 84%; prosthetic conduits were implanted in 38%. Seventy-four grafts were created in 57
patients with one or more serologically proven hypercoagulable states, including heparin-induced platelet aggregation
(n  37), anticardiolipin antibodies (n  11), lupus anticoagulant (n  8), protein C or S deficiency (n  7),
antithrombin III deficiency (n 3), and factor V Leiden mutation (n 1). Patients with hypercoagulability were younger
(63 2 years versus 69 1 years; P .007), more likely to have undergone prior revascularization attempts (38% versus
21%; P .003), and more likely to have chronic anticoagulation therapy after surgery (46% versus 25%; P .001). After
5 years (median follow-up, 19 months), patients with hypercoagulability had poorer primary patency (28%  7% versus
35%  5%; P  .004), primary assisted patency (37%  7% versus 45%  6%; P  .0001), secondary patency (41%  7%
versus 53%  6%; P  .0001), limb salvage (55%  8% versus 67%  6%; P  .009), and survival (61%  8% versus 74%
 4%; P .02) rates. Multivariate analysis identified only prosthetic conduit choice (P .0001), hypercoagulability (P
.0003), and limb salvage indication (P  .01) as independent predictors of graft failure.
Conclusion: Patients with serologically proven hypercoagulability have inferior long-term patency, limb salvage, and
survival rates after infrainguinal bypass. The high prevalence rate (13%) of diverse hypercoagulable states in this patient
population supports serologic screening, especially in referral practices. (J Vasc Surg 2003;37:301-6.)
The presence of hypercoagulability in patients with
arterial insufficiency is being increasingly recognized,1-5
particularly in patients with failed revascularization at-
tempts in the early postoperative period.6-10 Less is known
about the potential impact of hypercoagulability on the
long-term patency of infrainguinal bypass grafts. This ret-
rospective analysis was undertaken to evaluate the long-
term results of infrainguinal bypass grafting in patients with
serologically proven hypercoagulable states as compared
with a concurrent cohort of patients without documented
hypercoagulability.
METHODS
A retrospective review was performed of all patients
who underwent infrainguinal revascularization at The Uni-
versity of Chicago during the period from January 1994 to
January 2001. Hospital records, vascular clinic notes, and
vascular laboratory reports were reviewed, and a database
was compiled.
All laboratory records of this cohort were queried for
the presence of known indicators of hypercoagulability,
including heparin-induced platelet aggregation (HIPA),
protein C or S deficiency, factor V Leiden mutation, anti-
thrombin III deficiency, lupus anticoagulant, and anticar-
diolipin antibodies. The entire laboratory profiles of all
patients were reviewed by a clinical hematologist (JMB)
before inclusion in the cohort. Chronic anticoagulation
therapy was left to the discretion of the operating surgeon,
but in general, patients on transient or permanent antico-
agulation therapy included those without contraindication
who were shown to have non-HIPA hypercoagulability,
repeated graft failure, chronic atrial fibrillation, indwelling
prosthetic cardiac valve, or deep venous thrombosis. Poor
outflow or use of a prosthetic peripheral graft were only
relative indications for anticoagulation therapy in this se-
ries.
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Patient characteristics, indications, outflow character-
ization, operative data, complications, patency, limb sal-
vage, and survival data were tabulated. Indications, outflow
characterizations, patency, limb salvage, and survival are
reported in accordance with the Society for Vascular Sur-
gery/International Society for Cardiovascular Surgery Ad
Hoc Committee recommended standards for reports deal-
ing with lower extremity ischemia.11 Statistical analyses
were performed with SPSS for Windows software (SPSS,
Inc, Chicago, Ill). Patient characteristics, indications, and
complications were compared with Pearson 2 analysis.
Mann-Whitney tests were used for nonparametric compar-
ison of means. Patency, limb salvage, and survival rates were
compared with log-rank analysis. Patient factors identified
as statistically significant at a level of P less than .10 were
subjected to multivariate analysis with the Cox propor-
tional hazards model. Those factors that retained signifi-
cance at a level of P less than .05 after multivariate analysis
were considered independent.
RESULTS
Five hundred eighty-two consecutive infrainguinal by-
pass grafts were created in 456 patients over the period of
study. The indication for surgery was limb-threatening
ischemia in 84%; prosthetic conduits were implanted in
38%. Eighty-two patients (18%) underwent serologic eval-
uation for hypercoagulability, and 57 (13% of total) were
found to be positive for one or more conditions. Positive
tests included HIPA (n  37), anticardiolipin antibodies
(n  11), lupus anticoagulant (n  8), protein C or S
deficiency (n 7), antithrombin III deficiency (n 3), and
factor V Leiden mutation (n  1). Throughout the study
period, 74 grafts were created in these 57 patients. The
presence of a hypercoagulable state was known at the time
of operation in 19 of 74 grafts (26%). In general, patients
with known HIPA underwent intraoperative anticoagula-
tion with hirudin (Lepirudin, Aventis, Strasbourg, France),
and patients with other known defects underwent intraop-
erative anticoagulation with heparin and postoperative an-
ticoagulation with warfarin.
The patients were separated into the following two
groups for the purpose of comparison: those with docu-
mented hypercoagulability (57 patients, 64 limbs, 74
grafts) and the remainder (399 patients, 465 limbs, 508
grafts). Separation of the cohort into more than two groups
yielded cohorts of very small size, precluding meaningful
statistical analysis. The two groups were reasonably well
matched, albeit with some notable differences. Although
patients were similar in regard to the presence of major risk
factors and comorbidities (Table I), the patients with hy-
percoagulability were younger (63 2 years versus 69 1
years; P  .007). And, although the groups did not differ
significantly with respect to indication for operation, con-
duit type, or level of distal anastomosis, a greater propor-
tion of bypass grafts constructed in patients with hyperco-
agulability were redo operations (38% versus 21%; P 
.003) and chronic anticoagulation was used after surgery in
a greater percentage (47% versus 25%; P .001; Table II).
Early results are given in Table III. The hypercoagula-
ble group had a significantly longer median length of stay
(9 versus 6 days; P  .05) and higher rate of acute graft
failure (14% versus 7%; P  .06). The incidence rates of
Table I. Patient demographics and risk factors
Normal
(n  508)
Hypercoagulable
(n  74)
Total
(n  582)
Age (Y; mean  SEM) 68  1 63  2* 67  1
Female gender 250 (49%) 40 (54%) 290 (50%)
HTN 377 (74%) 56 (76%) 434 (75%)
DM 280 (55%) 33 (45%) 313 (54%)
CAD 281 (55%) 42 (57%) 323 (55%)
Smoking 274 (54%) 45 (61%) 319 (55%)
ESRD 91 (18%) 13 (18%) 104 (18%)
Previous CABG 99 (19%) 13 (18%) 112 (19%)
COPD 43 (8%) 5 (7%) 48 (8%)
*P  .05 compared with normal.
SEM, Standard error of means; HTN, hypertension; DM, diabetes mellitus;
CAD, coronary artery disease; ESRD, end stage renal disease; CABG,
coronary artery bypass graft; COPD, chronic obstructive pulmonary disease.
Table II. Surgical indications and anatomy
Normal Hypercoagulable Total
Limb salvage 428 (84%) 62 (84%) 490 (84%)
Redo 109 (21%) 28 (38%)* 137 (24%)
Blind outflow 35 (7%) 5 (7%) 40 (7%)
Above-knee 160 (31%) 19 (26%) 179 (31%)
Distal 261 (52%) 36 (49%) 297 (51%)
Autogenous 299 (59%) 41 (55%) 340 (58%)
Coumadin 121 (25%) 33 (47%)* 154 (27%)
Blind outflow designates outflow score of 0 according to Society for Vascular
Surgery/Interaction Society for Cardiovascular Surgery Ad Hoc Committee
reporting standards.11
*P  .05 compared with normal.
Table III. Lengths of stay and complications
Normal Hypercoagulable Total
Median LOS (d) 6 9 6
Major complications
MI/CHF 8 (2%) 0 8 (1%)
Sepsis/ARDS 5 (1%) 2 (3%) 7 (1%)
Stroke 6 (1%) 0 6 (1%)
Dialysis 2 (.01%) 1 (1%) 3 (1%)
Total 21 (4%) 3 (4%) 24 (4%)
Minor complications
Wound infection 46 (9%) 7 (10%) 53 (9%)
Hematoma 30 (6%) 6 (8%) 36 (6%)
GI bleed 5 (1%) 1 (1%) 6 (1%)
Pneumonia 5 (1%) 0 5 (1%)
Lymph leak 2 (.01%) 0 2 (.01%)
Total 88 (17%) 14 (19%) 102 (18%)
30-d graft failure 38 (7%) 10 (14%)* 48 (8%)
30-d amputation 20 (4%) 3 (4%) 23 (4%)
30-d mortality 13 (3%) 3 (4%) 16 (3%)
*P  .06 compared with normal.
LOS, length of stay; ARDS, adult respiratory distress syndrome; GI, gastro-
intestinal; MI, myocardial infarction; CHF, congestive heart failure.
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minor and major complications were similar between the
two groups (Table III).
Patients were followed for a median of 19 months
(range, 0.1 to 84 months). At 5 years, patients with hyper-
coagulability had poorer primary patency (28% 7% versus
35% 5%; P .004; Fig 1), primary assisted patency (37%
 7% versus 45%  6%; P  .0001), secondary patency
(41%  7% versus 53%  6%; P  .0001; Fig 2; Tables IV
and V, online only), limb salvage (55%  8% versus 67% 
6%; P .009; Fig 3), and survival (61% 8% versus 74%
4%; P .02; Fig 4) rates. Patency rate was particularly poor
in patients with hypercoagulability in whom prosthetic
conduits were implanted (3-year secondary patency rate for
prosthetic conduits, 21%  11% versus autogenous con-
duits, 55%  9%; P  .05).
Univariate analysis of risk factors for secondary graft
failure included the presence of hypercoagulability (P 
.0001), the use of prosthetic conduit (P  .0001), female
gender (P  .019), limb salvage indication (P  .019),
coronary artery disease (P  .03), prior coronary artery
bypass grafting (P .07), diabetes mellitus (P .10), redo
operation (P .10), end-stage renal failure (P .21), blind
outflow (P  .27), cerebrovascular disease (P  .53),
Fig 1. Cumulative primary assisted patency rate in 456 patients
undergoing infrainguinal bypass grafting with serologically proven
hypercoagulability (hypercoagulable, n  74 grafts) and without
(normal, n  508 grafts). Difference in patency rate was statisti-
cally significant with long-rank test (P  .05). All standard errors,
 10%.
Fig 2. Cumulative secondary patency rate in 456 patients under-
going infrainguinal bypass grafting with serologically proven hy-
percoagulability (hypercoagulable, n  74 grafts) and without
(normal, n  508 grafts). Difference in patency rate was statisti-
cally significant with long-rank test (P  .05). All standard errors,
10%.
Fig 3. Cumulative limb salvage rate for 456 patients undergoing
infrainguinal bypass grafting with serologically proven hyperco-
agulability (hypercoagulable, n  64 limbs) and without (normal,
n  465 limbs). Difference in limb salvage rate was statistically
significant with long-rank test (P  .05). All standard errors,
10%.
Fig 4. Cumulative survival rate in 456 patients undergoing in-
frainguinal bypass grafting with serologically proven hypercoagu-
lability (hypercoagulable, n  57) and without (normal, n  399).
Difference in survival rate was statistically significant with long-
rank test (P  .05). All standard errors, 10%.
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chronic obstructive pulmonary disease (P  .55), smoking
(P  .65), hypertension (P  .75), and left-sided bypass
(P  .86). Multivariate analysis identified only prosthetic
conduit choice (P  .0001), hypercoagulability (P 
.0003), and limb salvage indication (P  .01) as indepen-
dent predictors of graft failure.
DISCUSSION
Vascular surgeons are increasingly challenged to sal-
vage limbs in patients with more serious comorbidities,
more pronounced ischemia, and limited available autoge-
nous conduit.12-14 Moreover, it has gradually become rec-
ognized that many patients with critical lower extremity
ischemia also have accompanying rheologic conditions that
predispose to thrombosis.1-5,15,16 These conditions not
only hasten the occlusive process but also complicate revas-
cularization procedures and potentially threaten long-term
outcome. Although many reports document the type and
frequency of hypercoagulable states in vascular surgical
patients, few have focused on the long-term implications of
hypercoagulable disorders in the management of lower
extremity occlusive disease.17,18
The frequency of hypercoagulable states in patients
needing infrainguinal bypass is alarmingly high and everin-
creasing as the panel of identifiable defects broadens. In a
prospective screening study, Donaldson et al3 identified
hypercoagulable states in 9.5% of patients at their practice.
Included in this group were both acquired (HIPA) and
congenital (protein C/S deficiency, antithrombin III defi-
ciency, and lupus anticoagulant) hypercoagulable defects.
Of the acquired conditions, the most important for the
vascular surgeon, and the most common in this study (8%
of patients), is the phenomenon of HIPA. HIPA has been
reported in 2% to 8% of patients having received heparin,
with an even higher frequency in patients having under-
gone cardiopulmonary bypass.3,4,9,19-23 Most affected pa-
tients simply have a drop in platelet count, which reverses
completely with discontinuation of heparin. Infrequently,
however, HIPA may degenerate into heparin-induced
thrombocytopenia (“white clot syndrome”) with massive
venous and arterial thromboembolism and disseminated
intravascular coagulation.24 Even with prompt treatment,
the full-blown syndrome is attended by serious morbidity
or mortality in up to 50% of cases.20 To avoid the potential
for thrombocytopenia and heparin-induced thrombocyto-
penia in patients with known HIPA, heparin should gener-
ally be avoided. Appropriate operative strategies may in-
clude continuous warfarin anticoagulation, local instillation
of saline solution with judicious clamp management, or
intermittent anticoagulation with recombinant hirudin
(Lepirudin; Refludan, Hoechst Marion Roussel Limited,
Auckland, New Zealand; 0.4 mg/kg bolus followed by
0.15 mg/kg/h infusion; half-life 1.3 h). Each of these
strategies was used in this series with success.
Next to HIPA, the second most frequently encoun-
tered serologic defect in this report was the presence of
circulating anticardiolipin antibodies (2.4%) or lupus anti-
coagulant (1.7%). These represent immunoglobulin G or
immunoglobulin M antibodies that interfere with phospho-
lipid-dependent coagulation assays, such as clotting time,
partial thromboplastin time, and prothrombin time. How
these antibodies function as procoagulants is unclear, but their
presence is generally accepted as a marker for hypercoagula-
bility. A positive test for one or both of these factors is
associated with significantly increased risk of early postopera-
tive thrombotic complications,10,25,26 although their long-
term implications are less clear.17 In this series and in oth-
ers,10,17 patients with known circulating anticardiolipin
antibodies or lupus anticoagulant were generally treated with
intraoperative and continuous postoperative heparin, fol-
lowed by long-term anticoagulation with warfarin.
Protein C or S deficiency was encountered relatively
infrequently in this series (1.5%), although it is generally
considered to be among the most thrombogenic of the
hypercoagulable states. Protein C is a vitamin K-dependent
protein that, when activated, inhibits clot formation by
inhibition of factors Va and VIIIa and enhances fibrinolysis
through the inhibition of tissue plasminogen activator.
Protein S, also a vitamin K-dependent factor, acts as a
cofactor for activated protein C. Congenital deficiency of
either of these proteins has been associated with extremely
high rates of venous thromboembolic events in young
patients4,27,28 and should be considered a risk factor for
early thrombosis after vascular surgery.7,18 As with anticar-
diolipin syndrome, perioperative prophylaxis with heparin
is indicated, followed by warfarin anticoagulation for the
lifetime of the graft.
Both antithrombin III deficiency and activated protein
C resistance via factor V Leiden mutation were infrequently
identified in this series (only four patients), although, as
stated, their frequency is likely grossly underestimated be-
cause only 18% of the total patient pool was tested. Factor
V Leiden mutation is particularly prevalent in patients with
vascular disease, with the incidence rate reported as high as
26% in older patients with venous thrombosis29 and 16% in
arterial occlusive disease.30 Its prevalence is probably lower
in this series, however, because it is rare in African Ameri-
cans, who comprised more than half of the study group.31
Although its exact functional significance is yet to be de-
fined, factor V Leiden is clearly a risk factor for venous
thromboembolic disease28,32 and may predispose to graft
failure as well.5,6,18,30
The purpose of this retrospective study was to test the
hypothesis that the presence of one of more of these factors
would lead to poorer outcome after infrainguinal bypass
grafting. Although the hypercoagulable syndromes are clearly
heterogeneous in their biochemistry and natural history, all
were lumped together to maximize the statistical power of the
analysis. Taken as a group, the patients with clearly demon-
strable hypercoagulability had statistically significantly poorer
outcome with respect to patency, limb salvage, and survival.
Along with conduit choice and limb salvage indication, hyper-
coagulability was an independent predictor of graft failure
with multivariate analysis. The finding of decreased long-term
survival is particularly noteworthy and has not, to our knowl-
edge, been previously reported.
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Several limitations are obviously evident in this retro-
spective study. Only a minority of patients was tested, and
the most frequent impetus for initiating a serologic evalu-
ation for hypercoagulability was, of course, an adverse clinical
event. All of the patients with serologically proven hyperco-
agulability were lumped together for the purposes of analysis,
although clearly they represent a heterogeneous group. The
patients in the hypercoagulable group were more likely to
have undergone a prior revascularization attempt (38% versus
21%), so the cohorts were not well matched and a poorer
outcome may have been a foregone conclusion. The results
are compelling nonetheless because they suggest that a high
percentage of patients with adverse clinical events are eventu-
ally found to have demonstrable hypercoagulable defects and
that, although the defects are identified and ostensibly treated,
long-term outcomes remain compromised. Indeed, although
a higher percentage of patients (47% versus 25%) with hyper-
coagulability received long-term warfarin, their outcome was
still substandard.
In conclusion, patients with serologically proven hyper-
coagulability have inferior long-term patency, limb salvage,
and survival rates after infrainguinal bypass. The high prev-
alence rate (13%) of diverse hypercoagulable states in this
patient population supports serologic screening, especially
in patients with prior adverse events undergoing revascu-
larization in referral practices.
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DISCUSSION
Dr Magruder C. Donaldson (Boston, Mass). There are a
couple of questions I would like to ask about this very interesting
and well-presented paper. You evidently sampled about 18% of the
patients in your series. The ones in your control group were not
tested and therefore might have been positive, although your
overall prevalence of about 13% is not too far from findings of
other series using more systematic screening for known hyperco-
agulable states. Assuming you had sufficient prescience to be able
to identify hypercoagulable people on clinical grounds, what were
the clinical criteria that led you to testing in the minority of your
series tested?
The negative impact of hypercoagulability on graft failure
within 30 days of surgery is well established. The long-term
impact, particularly with regard to patient survival, is less well
documented and your data today are therefore of great interest.
Connecting a blood sample at the time of surgery with a remote
event such as graft failure or death is difficult, however. For
example, some of the hypercoagulable states that you found may in
fact be temporary and may not persist over months or years of
follow-up. Deficiencies of regulatory proteins such as protein C are
commonly transient, and the heparin antibody often becomes
undetectable on serial testing. I am wondering whether you fol-
lowed the hypercoagulable patients with serial sampling and were
thus able to more directly connect the persistence of hypercoagu-
lable states with the later events you report.
Dr Michael A. Curi. The first question, these patients who
underwent screening for hypercoagulable states, were largely
tested as a consequence of a clinical event such as early graft failure
or a history of venous thrombosis. So, it could be said that the
group is selected to do worse in that the reason for the screening
originally, in a large percentage of the patients, was a thrombotic
event.
But I think it is important that, even though this screening was
done after a thrombotic event, to ascertain whether these patients
do have a hypercoagulable state, because the subsequent treatment
may change. So, as far as which patients to test, I think certainly in
referral practices or patients who are referred with concomitant
illnesses, such as lupus or previous exposure to heparin or previous
failed bypass attempt, I think those are the patients we really should
be screening. And we are starting to do that at the University of
Chicago.
As far as the second question, we did not look at the presence
over a long period of time of these factors. So, if the patients at any
point were documented to have one of these hypercoagulable
syndromes, they were placed into our hypercoagulable group
based on review by a clinical hematologist.
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Table IV, online only. Secondary patency rate of 508
grafts in patients without known hypercoagulable state
Interval
(mos)
No. grafts
entering
interval
No.
failures
No.
withdrawn
Interval
patency
rate
Cumulative
secondary
patency rate SEM
0-3 508 34 120 92% 92% 1%
3-6 354 27 58 92% 85% 2%
6-9 269 12 37 95% 81% 2%
9-12 220 13 23 94% 76% 2%
12-15 184 4 18 98% 74% 2%
15-18 162 4 23 97% 72% 3%
18-21 135 2 14 98% 71% 3%
21-24 119 1 19 99% 70% 3%
24-27 99 4 10 96% 67% 3%
27-30 85 1 13 99% 66% 3%
30-33 71 2 11 97% 64% 3%
33-36 58 1 7 98% 63% 3%
36-39 50 1 12 98% 62% 4%
39-42 37 0 8 100% 62% 4%
42-45 29 0 4 100% 62% 4%
45-48 25 1 7 95% 59% 4%
48-51 17 0 1 100% 59% 4%
51-54 16 1 5 93% 54% 6%
54-57 10 0 0 100% 54% 6%
57-60 10 0 1 100% 54% 6%
SEM, Standard error of mean.
Table V, online only. Secondary patency rate of 74
grafts in patients with serologicaly proven
hypercoagulability
Interval
(mos)
No. grafts
entering
interval
No.
failures
No.
withdrawn
Interval
patency
rate
Cumulative
secondary
patency rate SEM
0-3 74 12 10 83% 83% 5%
3-6 52 9 4 82% 68% 6%
6-9 39 5 2 87% 59% 6%
9-12 32 2 2 94% 55% 6%
12-15 28 0 1 100% 55% 6%
15-18 27 1 3 96% 53% 7%
18-21 23 2 3 91% 48% 7%
21-24 18 1 0 94% 45% 7%
24-27 17 0 3 100% 45% 7%
27-30 14 1 1 93% 42% 7%
30-33 12 0 0 100% 42% 7%
33-36 8 0 4 100% 42% 7%
36-39 6 0 2 100% 42% 7%
39-42 5 0 1 100% 42% 7%
42-45 5 0 0 100% 42% 7%
45-48 4 0 1 100% 42% 7%
48-51 3 0 1 100% 42% 7%
51-54 2 0 1 100% 42% 7%
54-57 1 0 0 100% 42% 7%
57-60 1 0 0 100% 42% 7%
SEM, Standard error of mean.
1
